Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes.

NCT04061421 is registered in ClinicalTrials.gov with Michael Savona as lead sponsor.

NCT NCT04061421
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04061421 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes.
Lead sponsor
Michael Savona
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 24, 2021
Completion date
December 31, 2027
Enrollment
94 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

mds/mpn